Results of the cooperative protocol (N-III-95) for metastatic relapses and refractory neuroblastoma

Castel, Victoria; Ca�ete, A.; Melero, Carmen; Acha, T.; Navajas, A.; Garc�a-Miguel, P.; Contra, T; Molina, J.; Galar�n, P.; Cruz, Ofelia

doi:10.1002/1096-911x(20001201)35:6<724::aid-mpo53>3.0.co;2-u

Cited by 13 publications

(6 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Current relapsed/refractory neuroblastoma protocols utilizing 131 I‐mIBG alongside high‐dose chemotherapy and autologous stem cell rescue (ASCR) also demonstrate outcome improvement but not significantly increased long‐term survival . Several recent European studies show efficacy of 131 I‐mIBG as an induction monotherapy or in combination with multiple‐drug chemotherapy for newly diagnosed high‐risk neuroblastoma .…”

Section: Norepinephrine Transporter Functionmentioning

confidence: 99%

Nothing but NET: A review of norepinephrine transporter expression and efficacy of ¹³¹I‐mIBG therapy

Streby

Shah

Ranalli

et al. 2014

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Neuroblastoma is unique amongst common pediatric cancers for its expression of the norepinephrine transporter (NET), enabling tumor-selective imaging and therapy with radioactive analogues of norepinephrine. The majority of neuroblastoma tumors are avid for 123I-metaiodobenzaguanidine (mIBG) on imaging, yet the therapeutic response to 131I-mIBG is only 30% in clinical trials, and off-target effects cause short- and long-term morbidity. We review the contemporary understanding of the tumor-selective uptake, retention, and efflux of meta-iodobenzylguanidine (mIBG) and strategies currently in development for improving its efficacy. Combination treatment strategies aimed at enhancing NET are likely necessary to reach the full potential of 131I-mIBG therapy.

show abstract

Section: Norepinephrine Transporter Functionmentioning

confidence: 99%

Nothing but NET: A review of norepinephrine transporter expression and efficacy of ¹³¹I‐mIBG therapy

Streby

Shah

Ranalli

et al. 2014

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…7 The randomized study of the Children's Oncology Group showed significantly better outcome in patients treated post-ASCT with the anti-G D2 chimeric mAb ch14.18 plus granulocyte-macrophage colony-stimulating factor (GM-CSF) plus interleukin-2. 8 Nevertheless, relapse remains common and carries a dismal prognosis, [9][10][11][12][13][14][15][16][17] and has been deemed to be "invariably fatal" in a recent review. 1 Adverse prognostic factors for duration of survival post relapse include short time to first relapse and MYCN amplification.…”

Section: Introductionmentioning

confidence: 99%

Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G_D2immunotherapy and isotretinoin: a prospective Phase II study

et al. 2015

View full text Add to dashboard Cite

Relapse of high-risk neuroblastoma (HR-NB) is deemed invariably fatal yet increasing numbers of HR-NB patients achieve a second complete/very good partial remission (CR/VGPR), hence the urgency to find a successful consolidative therapy. Identifying efficacy in patients without assessable disease, however, is problematic. We report the first study providing outcome data for this group of patients with poor prognosis. To prevent another relapse, HR-NB patients in second or later CR/VGPR received the anti-G D2 murine antibody 3F8 plus granulocyte-macrophage colony-stimulating factor plus isotretinoin in a Phase II trial. Upon meeting the target aim for progression-free survival (PFS) in the initial cohort of 33 patients, the trial was amended to allow patients who developed human anti-mouse antibody (HAMA) to receive rituximab to ablate HAMA with or without low-dose maintenance chemotherapy until immunotherapy could resume. For the total of 101 study patients, 5-year PFS and overall survival (OS) rates were 33% § 5% and 48% § 5%, respectively. Among the 33 long-term progression-free survivors, 19 had MYCN amplification, 19 had previously received anti-G D2 immunotherapy plus isotretinoin (as first-line therapy), and 15 never received maintenance chemotherapy. In a multivariate analysis of prognostic factors, only absence of minimal residual disease in bone marrow after 2 cycles of immunotherapy and before initiation of isotretinoin or anti-HAMA therapy was significantly favorable for both PFS and OS. Therefore, long-term PFS is possible for HR-NB patients who achieve at least a second CR/VGPR and receive consolidation that includes anti-G D2 immunotherapy plus isotretinoin, even if the patients received these biological treatments before relapse. Results from this prospective study will aid in the development of future Phase II studies for this growing ultra high-risk patient population.

show abstract

“…It is derived from primitive cells of the sympathetic nervous system and approximately 50% of all neuroblastomas arise in the adrenal medulla. Although the treatment outcome for children with advanced stage neuroblastoma has improved, 5-year event free survival in most studies is less than 30% (Castel et al, 2000(Castel et al, , 2001. In a few studies, survival reaching 34% has been reported in patients with N-myc amplification (>10 copies) receiving intensified regimens of cytotoxic agents (Kaneko et al, 2002).…”

mentioning

confidence: 99%

Proapoptotic compound ARC targets Akt and N-myc in neuroblastoma cells

et al. 2007

View full text Add to dashboard Cite

We have previously described the identification of a nucleoside analog transcriptional inhibitor ARC (4-amino-6-hydrazino-7-b-D-ribofuranosyl-7H-pyrrolo[2,3-d]-pyrimidine-5-carboxamide) that was able to induce apoptosis in cancer cell lines of different origin. Here, we report the characterization of ARC on a panel of neuroblastoma cell lines. We found that these cell lines were more than 10-fold sensitive to ARC than to the well-known nucleoside analog DRB (5,6-dichloro-1-b-Dribofuranosylbenzimidazole), and that ARC-induced apoptosis proceeds through mitochondrial injury. Also, we observed that ARC-mediated cell death was accompanied by caspase-3 cleavage and repression of antiapoptotic proteins such as Mcl-1 and survivin. Conversely, we found that overexpression of Mcl-1-protected neuroblastoma cell line NB-1691 from ARC-induced apoptosis. Furthermore, we found that while ARC inhibited the phosphorylation of Akt Ser-473 in multiple cancer cell lines, forced expression of myristoylated Akt promoted resistance to ARC-induced apoptosis in neuroblastoma cells. In addition, we observed that ARC was able to downregulate the protein levels of N-myc, a commonly amplified oncogene in neuroblastomas, and Akt protected N-myc from ARCinduced downregulation. These data suggest that ARC may antagonize different antiapoptotic pathways and induce apoptosis in neuroblastoma cells via multiple mechanisms. Overall, ARC could represent an attractive candidate for anticancer drug development against neuroblastomas.

show abstract

Results of the cooperative protocol (N-III-95) for metastatic relapses and refractory neuroblastoma

Abstract: This approach is feasible and toxicity manageable; it rescued some patients and prolonged their survival. It merits assay in newly diagnosed high-risk neuroblastoma patients.

Cited by 13 publications

References 7 publications

Nothing but NET: A review of norepinephrine transporter expression and efficacy of ¹³¹I‐mIBG therapy

Nothing but NET: A review of norepinephrine transporter expression and efficacy of ¹³¹I‐mIBG therapy

Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G_D2immunotherapy and isotretinoin: a prospective Phase II study

Proapoptotic compound ARC targets Akt and N-myc in neuroblastoma cells

Contact Info

Product

Resources

About

Results of the cooperative protocol (N-III-95) for metastatic relapses and refractory neuroblastoma

Abstract: This approach is feasible and toxicity manageable; it rescued some patients and prolonged their survival. It merits assay in newly diagnosed high-risk neuroblastoma patients.

Cited by 13 publications

References 7 publications

Nothing but NET: A review of norepinephrine transporter expression and efficacy of 131I‐mIBG therapy

Nothing but NET: A review of norepinephrine transporter expression and efficacy of 131I‐mIBG therapy

Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2immunotherapy and isotretinoin: a prospective Phase II study

Proapoptotic compound ARC targets Akt and N-myc in neuroblastoma cells

Contact Info

Product

Resources

About

Nothing but NET: A review of norepinephrine transporter expression and efficacy of ¹³¹I‐mIBG therapy

Nothing but NET: A review of norepinephrine transporter expression and efficacy of ¹³¹I‐mIBG therapy

Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G_D2immunotherapy and isotretinoin: a prospective Phase II study